gamma-Sarcoglycan deficiency increases cell contractility, apoptosis and MAPK pathway activation but does not affect...

Area of Science:

• Muscle biology
• Cellular signaling
• Biochemistry

Background:

• Gamma-sarcoglycan (gammaSG) is part of a membrane complex with dystroglycan.
• GammaSG deficiency causes limb-girdle muscular dystrophy.
• The precise functions of gammaSG in normal myotubes are not well understood.

Purpose of the Study:

• To investigate the functions of gamma-sarcoglycan (gammaSG) in skeletal muscle cells.
• To characterize the cellular phenotype of gammaSG-deficient myotubes.
• To explore the signaling pathways affected by gammaSG deficiency.

Main Methods:

• Comparison of gammaSG-deficient and normal myotubes in cell culture.
• Assessment of apoptosis rates.
• Measurement of contractile prestress and cell adhesion.
• Analysis of acto-myosin striations.
• Phosphoproteomic screening of signaling proteins.

Main Results:

• GammaSG-deficient myotubes showed a tenfold increase in apoptosis compared to normal cells.
• Deficient myotubes exhibited increased contractile prestress, leading to greater shortening and widening upon detachment.
• No significant difference in cell adhesion was observed.
• Prominent acto-myosin striations were noted in gammaSG-deficient myotubes.
• MAPK-pathway proteins and other signaling molecules showed altered phosphorylation patterns.

Conclusions:

• Gamma-sarcoglycan normally moderates contractile prestress in skeletal muscle.
• GammaSG plays a role in membrane-based signaling related to prestress and sarcomerogenesis.
• Understanding gammaSG function is crucial for limb-girdle muscular dystrophy research.